Why Is Chemed (CHE) Up 4.5% Since Last Earnings Report?

A month has gone by since the last earnings report for Chemed (CHE). Shares have added about 4.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.VGM ScoresCurrently, Chemed has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookChemed has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Performance of an Industry PlayerChemed is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, DaVita HealthCare (DVA), a stock from the same industry, has gained 3.9%. The company reported its results for the quarter ended December 2024 more than a month ago.DaVita HealthCare reported revenues of $3.29 billion in the last reported quarter, representing a year-over-year change of +4.7%. EPS of $2.24 for the same period compares with $1.87 a year ago.For the current quarter, DaVita HealthCare is expected to post earnings of $1.75 per share, indicating a change of -26.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.DaVita HealthCare has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chemed Corporation (CHE): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks